Skip to main navigation menu Skip to main content Skip to site footer

Review article: Biomedical intelligence

Vol. 149 No. 0910 (2019)

Treatment of chronic non-infectious uveitis and scleritis

  • Daniele C. Rossi
  • Camillo Ribi
  • Yan Guex-Crosier
Cite this as:
Swiss Med Wkly. 2019;149:w20025


Ocular inflammations such as uveitis and scleritis can lead to significant visual impairment if not treated properly. To limit potentially sight-threatening complications, good control of the inflammation in the acute phase is necessary. Corticosteroids have been the mainstay of ocular therapies for many years, but high doses of corticosteroids, which are required to maintain quiescence in severe uveitis, can be associated with many systemic and ocular complications. In order to limit steroid side-effects, classic immunosuppressant and immunobiologic agents have been widely used as steroid-sparing agents. In this review, we summarise the immunosuppressive drug therapy utilised in the treatment of ocular inflammatory diseases.


  1. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996 Apr;80(4):332–6.
  2. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004 Sep;88(9):1159–62.
  3. Jabs DA, Nussenblatt RB, Rosenbaum JT ; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–16. doi:.
  4. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004 Mar;111(3):491–500.
  5. Suhler EB, Lloyd MJ, Choi D, Rosenbaum JT, Austin DF. Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol. 2008;146(6):890–6.e8. doi:.
  6. Acharya NR, Tham VM, Esterberg E, Borkar DS, Parker JV, Vinoya AC, et al. Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. JAMA Ophthalmol. 2013;131(11):1405–12. doi:.
  7. Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin. 2005;45(2):1–13. doi:.
  8. Jakob E, Reuland MS, Mackensen F, Harsch N, Fleckenstein M, Lorenz H-M, et al. Uveitis subtypes in a german interdisciplinary uveitis center--analysis of 1916 patients. J Rheumatol. 2009;36(1):127–36. doi:.
  9. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14(5-6):303–8. doi:.
  10. Chylack LT, Jr, Bienfang DC, Bellows AR, Stillman JS. Ocular manifestations of juvenile rheumatoid arthritis. Am J Ophthalmol. 1975;79(6):1026–33. doi:.
  11. Cassidy JT, Sullivan DB, Petty RE. Clinical patterns of chronic iridocyclitis in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1977;20(2, Suppl):224–7.
  12. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. doi:.
  13. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513. doi:.
  14. Baker KB, Spurrier NJ, Watkins AS, Smith JR, Rosenbaum JT. Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Br J Ophthalmol. 2006 Dec;90(12):1481–5.
  15. Kheir V, Vaudaux J, Guex-Crosier Y. Review of the latest systemic treatments for chronic non-infectious uveitis. Expert Rev Ophthalmol. 2016;11(2):111–33. doi:.
  16. Doctor P, Sultan A, Syed S, Christen W, Bhat P, Foster CS. Infliximab for the treatment of refractory scleritis. Br J Ophthalmol. 2010 May;94(5):579–83.
  17. Beardsley RM, Suhler EB, Rosenbaum JT, Lin P. Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opin Pharmacother. 2013;14(4):411–24. doi:.
  18. Baeten D, van Hagen PM. Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational? Ann Rheum Dis. 2010;69(12):2067–73. doi:.
  19. Hardy S, Hashemi K, Catanese M, Candil M, Zufferey P, Gabison E, et al. Nekrotisierende Skleritis und periphere ulzerative Keratitis mit rheumatoider Arthritis: Therapie mit Rituximab. Klin Monatsbl Augenheilkd. 2017;234(4):567–70. doi:.
  20. Foster CS, Kothari S, Anesi SD, Vitale AT, Chu D, Metzinger JL, et al. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Surv Ophthalmol. 2016;61(1):1–17. doi:.
  21. Pleyer U, Algharably EA-H, Feist E, Kreutz R. Small molecules as therapy for uveitis: a selected perspective of new and developing agents. Expert Opin Pharmacother. 2017;18(13):1311–23. doi:.
  22. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005 Oct 20;353(16):1711–23.
  23. Armaly MF, Becker B. Intraocular pressure response to topical corticosteroids. Fed Proc. 1965;24(6):1274–8.
  24. Cantrill HL, Palmberg PF, Zink HA, Waltman SR, Podos SM, Becker B. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975;79(6):1012–7. doi:.
  25. Kothari S, Foster CS, Pistilli M, Liesegang TL, Daniel E, Sen HN, et al.; Systemic Immunosuppressive Therapy for Eye Diseases Research Group. The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis. Ophthalmology. 2015;122(10):1987–2001. doi:.
  26. Daniel E, Pistilli M, Kothari S, Khachatryan N, Kaçmaz RO, Gangaputra SS, et al.; Systemic Immunosuppressive Therapy for Eye Diseases Research Group. Risk of Ocular Hypertension in Adults with Noninfectious Uveitis. Ophthalmology. 2017;124(8):1196–208. doi:.
  27. Goldhardt R, Rosen BS. Uveitic Macular Edema: Treatment Update. Curr Ophthalmol Rep. 2016;4(1):30–7. doi:.
  28. Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group, Kempen JH, Altaweel MM, Holbrook JT, Sugar EA, Thorne JE, et al. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis. JAMA. 2017 May 16;317(19):1993–2005.
  29. Charkoudian LD, Ying G-S, Pujari SS, Gangaputra S, Thorne JE, Foster CS, et al. High-dose intravenous corticosteroids for ocular inflammatory diseases. Ocul Immunol Inflamm. 2012;20(2):91–9. doi:.
  30. Ishida Y, Matsuda H, Kida K. Effect of cyclosporin A on human bone marrow granulocyte-macrophage progenitors with anti-cancer agents. Acta Paediatr Jpn. 1995;37(5):610–3. doi:.
  31. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol. 2003;23(5):465–76. doi:.
  32. Yamada Y, Sugita S, Tanaka H, Kamoi K, Takase H, Mochizuki M. Timing of recurrent uveitis in patients with Behcet’s disease receiving infliximab treatment. Br J Ophthalmol. 2011;95(2):205–8. doi:.
  33. Lindstedt EW, Baarsma GS, Kuijpers RWAM, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89(5):533–6. doi:.
  34. Schewitz-Bowers LP, Lait PJP, Copland DA, Chen P, Wu W, Dhanda AD, et al. Glucocorticoid-resistant Th17 cells are selectively attenuated by cyclosporine A. Proc Natl Acad Sci USA. 2015;112(13):4080–5. doi:.
  35. Trotter JL, Rodey GE, Gebel HM. Azathioprine decreases suppressor T cells in patients with multiple sclerosis. N Engl J Med. 1982;306(6):365–6. doi:.
  36. Elion GB. The purine path to chemotherapy. Science. 1989;244(4900):41–7. doi:.
  37. Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500–509.e2. doi:.
  38. Gangaputra S, Newcomb CW, Liesegang TL, Kaçmaz RO, Jabs DA, Levy-Clarke GA, et al.; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–98.e1. doi:.
  39. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108(6):1134–9. doi:.
  40. Tappeiner C, Schenck S, Niewerth M, Heiligenhaus A, Minden K, Klotsche J. Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database. Arthritis Care Res (Hoboken). 2016 ;68(1):46–54.
  41. Lipsky JJ. Mycophenolate mofetil. Lancet. 1996;348(9038):1357–9. doi:.
  42. Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet. 1998;352(9121):35–6. doi:.
  43. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008 Aug;115(8):1416–21–1421.
  44. Teoh SC, Hogan AC, Dick AD, Lee RWJ. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol. 2008 Nov;146(5):752–60–760.
  45. Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, Gómez Vidal MA, Collantes Estévez E, Ramírez Chamond R, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33(5):251–5. doi:.
  46. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12(1):49–62. doi:.
  47. Fischer R, Kontermann R, Maier O. Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy. Antibodies. Multidisciplinary Digital Publishing Institute. 2015;4(1):48–70.
  48. Karampetsou MP, Liossis S-NC, Sfikakis PP. TNF-α antagonists beyond approved indications: stories of success and prospects for the future. QJM. 2010;103(12):917–28. doi:.
  49. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016 Sep 8;375(10):932–43.
  50. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–92. doi:.
  51. Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ, et al. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Ophthalmology. 2018;125(7):1075–87. doi:.
  52. Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et al.; SYCAMORE Study Group. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376(17):1637–46. doi:.
  53. Alessandri C, Scrivo R, Spinelli FR, Ceccarelli F, Magrini L, Priori R, et al. Autoantibody production in anti-TNF-alpha-treated patients. Ann N Y Acad Sci. 2007 Sep;1110(1):319–29.
  54. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000 Nov;43(11):2383–90.
  55. De Rycke L, Kruithof E, Van Damme N, Hoffman IEA, Van den Bossche N, Van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. Wiley-Blackwell; 2003 Apr;48(4):1015–23.
  56. Zein G, Berta A, Foster CS. Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm. 2004;12(2):137–42. doi:.
  57. Winthrop KL, Chen L, Fraunfelder FW, Ku JH, Varley CD, Suhler E, et al. Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol. 2013;155(1):183–189.e1. doi:.
  58. Jani M, Barton A, Warren RB, Griffiths CEM, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53(2):213–22. doi:.
  59. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan;48(1):35–45.
  60. van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004 May;63(5):508–16.

Most read articles by the same author(s)